EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitFallbericht

TP53 ‐Mutated Acute Myeloid Leukemia: Review of Treatment and Challenges

Bipin Ghimire iD, Markie Zimmer, Vijayalakshmi Donthireddy

European Journal of Haematology · 2025

DOI: 10.1111/ejh.14404 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift European Journal of Haematology, 2025. Verfasst von Bipin Ghimire und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology and Oncology, Henry Ford Health, Detroit, Michigan, USA. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Tumor Suppressor Protein p53, Mutation. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 59 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Patients with acute myeloid leukemia (AML) harboring mutations in TP53 ( TP53 ‐MT) have poor responses to current therapies and unfavorable prognoses. Despite the recognition of variant TP53 as an adverse feature of AML, an optimal treatment regimen has not yet been established, underlining a critical need for new, more effective therapeutic combinations and novel treatments. We present the case of a patient with TP53 ‐MT AML and marked myelodysplasia who developed primary refractory disease after induction therapy with the intensive chemotherapy regimen of liposomal daunorubicin and cytarabine. Our patient's optimal response to second induction chemotherapy with FLAG‐Ida prompted an exploration of established and investigational treatment regimens for this specific high‐risk AML subtype. Therefore, we performed a comprehensive literature review of findings from studies exploring AML therapies, focusing on outcomes for patients with TP53 ‐MT AML. The summary provided here reveals the complexity of defining the therapeutic responses of patients with the heterogeneous TP53 ‐MT genetic background and the challenges in treating this high‐risk form of AML. Future work must continue to investigate novel therapies and combinations to improve patient outcomes in this vulnerable population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Myeloid, AcuteTumor Suppressor Protein p53MutationHumansAntineoplastic Combined Chemotherapy ProtocolsTreatment OutcomeMaleDisease ManagementDaunorubicinMiddle AgedCytarabine

Stichwörter der Autor:innen

TP53acute myeloid leukemiamyelodysplasiap53

Substanzen

Tumor Suppressor Protein p53TP53 protein, humanDaunorubicinCytarabine

Autor:innen und Institutionen

  • Department of Hematology and Oncology, Henry Ford Health, Detroit, Michigan, USA.

ORCID-Profile: Bipin Ghimire

Zitieren

APA

Ghimire, B., Zimmer, M., & Donthireddy, V. (2025). TP53 ‐Mutated Acute Myeloid Leukemia: Review of Treatment and Challenges. European Journal of Haematology. https://doi.org/10.1111/ejh.14404

Vancouver

Ghimire B, Zimmer M, Donthireddy V. TP53 ‐Mutated Acute Myeloid Leukemia: Review of Treatment and Challenges. European Journal of Haematology. 2025. doi:10.1111/ejh.14404

BibTeX
@article{Ghimire2025,
  author = {Ghimire, Bipin and Zimmer, Markie and Donthireddy, Vijayalakshmi},
  title = {TP53 ‐Mutated Acute Myeloid Leukemia: Review of Treatment and Challenges},
  journal = {European Journal of Haematology},
  year = {2025},
  doi = {10.1111/ejh.14404}
}
Kostenlos starten →